Dianthus Therapeutics, Inc. Common Stock
DNTHDianthus Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for rare and life-threatening diseases. The company utilizes innovative approaches in protein engineering and drug discovery to create treatments that address unmet medical needs, particularly in the fields of hematology and immunology. Founded with the goal of advancing precision medicine, Dianthus aims to improve patient outcomes through its specialized therapeutics.
Company News
The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence...
Dianthus Therapeutics CFO Ryan Savitz sold 20,000 shares worth $903,600 on December 4, 2025, completely eliminating his direct equity holdings. The sale was executed through exercise and immediate sale of vested stock options at a weighted average price of $45.18 per share. Despite the insider selling, the stock has retreated from its 52-week hig...
Dianthus Therapeutics, a clinical-stage biotech company focused on severe autoimmune diseases, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Marino Garcia will present a corporate overview and meet with investors. The company is also advancing its lead candidate LBL-047 (DNTH212), a bifu...
Dianthus Therapeutics reported successful Phase 2 trial results for claseprubart in generalized Myasthenia Gravis, demonstrating promising treatment effects and announcing plans for a Phase 3 trial in 2026.
Dianthus Therapeutics has entered an exclusive licensing agreement with Leads Biolabs for DNTH212, a bifunctional fusion protein targeting autoimmune diseases. The agreement involves up to $38 million in initial payments and potential milestone payments up to $962 million, with Dianthus gaining global rights outside Greater China.
